A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Completed · Phase 3 · Has a placebo group

Conditions studied: Severe Hypertriglyceridemia

In brief

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

Key facts

Study ID
NCT05552326
Run by
Ionis Pharmaceuticals, Inc.
People needed
446
Starts
2022-08-31
Expected to finish
2025-09-12
Last updated by the study team
2025-10-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.